Upper Sequential Distalization With TADs and Aligners
Launched by UNIVERSIDAD COMPLUTENSE DE MADRID · Apr 30, 2021
Trial Information
Current as of May 24, 2025
Unknown status
Keywords
ClinConnect Summary
In this study the investigators are going to assess and compare the predictability of distal movement of upper molars in patients with class II molar relationship when superimposing the initial malocclusion with the real end of distalization phase and the predicted end of distalization phase. Also, the investigators are going to study another dental movements, pain level, aligner properties, oral hygiene, posterior root resorption, patient satisfaction, quality of life and efficiency of these systems.
The aligner systems that are going to be used are Invisalign System (Align Technology, Sa...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who needed orthodontic treatment with aligners in both jaws.
- • Adult patients (\>18 years)
- • Full permanent dentition (excluding third molars)
- • Patients with non-surgical or non-extraction (excluding third molars) treatment
- • No active periodontal disease
- • Patients with class II molar relationship that needed molar distalization
- Exclusion Criteria:
- • Patients with systemic diseases affecting bone metabolism or teeth or inflammatory diseases
- • Patients undergoing treatment with immunosuppressant or bisphosphonates
- • Patients undergoing chemo and radiotherapy
- • Patients with any other syndrome-associated orofacial deformation, cleft lip or palate
- • Pregnant women or non(or poor)-compliance patients with skeletal discrepancies
- • Patients with dental or skeletal crossbite that need 3 mm or more per side of expansion
About Universidad Complutense De Madrid
The Universidad Complutense de Madrid (UCM) is a prestigious academic institution renowned for its commitment to research and innovation in various fields, including health sciences. As a prominent sponsor of clinical trials, UCM leverages its extensive resources and expertise to advance medical knowledge and improve patient outcomes. The university fosters collaboration among researchers, clinicians, and industry partners, ensuring the highest standards of ethics and scientific rigor in its clinical research initiatives. UCM's dedication to education and research excellence positions it as a leader in the development of new therapeutic interventions and health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Trial Officials
Alejandro Iglesias Linares
Study Director
Universidad Complutense de Madrid
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials